Background And Purpose: Diabetic nephropathy (DN) is an important cause of end-stage renal disease, with podocyte injury as the main feature. Pyroptosis plays a non-negligible role in the process of diabetic nephropathy. Puerarin (PR) treatment of diabetic nephropathy has great potential, but the mechanism is not very clear. This article aims to study the protective effect and mechanism of puerarin on DN.
Methods: Streptozotocin (STZ)-induced C57 BL/6J mouse model of DN was given PR, Necrosulfomide (NSA), Nigericin for 12 weeks; A 60 mM high glucose(HG) induced MPC5 cell injury model was administered to PR, NSA, and Nigericin interventions for 24 h.
Results: After 12 weeks of administration, PR reduced fasting blood glucose levels in DN mice, alleviated glomerular lesions, reduced podocyte damage, and protected renal function. Meanwhile, PR also inhibits the expression of pyroptosis-related proteins. In addition, PR alleviated the release of Interleukin 18 (IL-18), Interleukin 1beta (IL-1β), and lactate dehydrogenase (LDH) in MPC5 cells under HG conditions, downregulated the expression of pyrozozois-related proteins, and improved Caspase-1-mediated pyroptosis in MPC5 cells.
Conclusion: Our study suggests that the beneficial effects of PR in diabetic nephropathy may be associated with inhibition of Caspase-1-mediated pyroptosis.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/jpp/rgad113 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comparison of complete blood count parameters in different severity of proteinuria among patients with type 2 diabetes mellitus.
J Res Med Sci
October 2024
Clinical Research and Development Center, Shahid Modarres Hospital, Division of Nephrology, Department of Internal Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Background: Proteinuria is a key indicator of kidney damage in diabetic nephropathy, and its severity correlates with the progression of the disease. In diabetic patients, it is crucial to identify reliable predictors for proteinuria and its severity for early detection and management of kidney damage.
Materials And Methods: This cross-sectional study was conducted from November 16, 2022, to May 20, 2023, on patients with type 2 diabetes mellitus (T2DM) who were outpatients at clinics of Shahid Modarres Hospital, Tehran, Iran.
Natural products as Nrf2 modulators for ferroptosis inhibition in renal disease therapy: Recent progress and future prospects.
Phytomedicine
December 2024
State Key Laboratory of Quality Research in Chinese Medicine, Faculty of Chinese Medicine, Macau University of Science and Technology, Macau 999078, China; State Key Laboratory of Traditional Chinese Medicine Syndrome, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510006, China; Chinese Medicine Guangdong Laboratory (Hengqin Laboratory), Guangdong-Macao In-Depth Cooperation Zone in Hengqin, 519000, China. Electronic address:
Background: The transcription factor Nrf2 (nuclear factor erythroid 2-related factor 2, NFE2L2) is a pivotal regulator of redox balance, metabolism, protein homeostasis and inflammation. Nrf2 is critically involved in both ferroptosis and renal diseases, and may serve as a significant target for many natural products in the treatment of renal diseases. However, a comprehensive overview on this topic is still lacking.
View Article and Find Full Text PDFGut-kidney interaction reinforces dapagliflozin-mediated alleviation in diabetic nephropathy.
Am J Physiol Cell Physiol
December 2024
Department of Nephrology, the First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, Zhejiang, 310000, China.
Intestinal microbiota are pathophysiologically involved in diabetic nephropathy (DN). Dapagliflozin, recognized for its blood glucose-lowering effect, has demonstrated efficacy in improving DN. However, the mechanisms beyond glycemic control that mediate the impact of dapagliflozin on DN remain unclear.
View Article and Find Full Text PDFNetwork pharmacology, molecular docking, and experimental verification to reveal the mechanism of colquhounia root tablet in the treatment of diabetic nephropathy.
Biochem Biophys Res Commun
December 2024
Department of Nephrology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China. Electronic address:
Article Synopsis
- Diabetic nephropathy (DN) is a common complication of diabetes, and Colquhounia Root Tablet (CRT) has shown potential therapeutic effects, although its mechanisms are not fully understood.
- Using various databases, researchers identified 163 therapeutic targets of CRT related to DN and found key targets like STAT3 and IL6 through protein-protein interaction analysis.
- The study highlighted the AGEs/RAGE signaling pathway as significant for CRT's effectiveness against DN and confirmed its protective effects on kidney cells via experimental treatments, although further studies are required to assess the safety and efficacy in real-life scenarios.
High glucose promotes macrophage switching to the M1 phenotype via the downregulation of STAT-3 mediated autophagy.
PLoS One
December 2024
Institute of Nephrology, Zhong Da Hospital, School of Medicine, Southeast University, Nanjing Jiangsu, China.
Aim: Imbalanced M1/M2 macrophage phenotype activation is a key point in diabetic kidney disease (DKD). Macrophages mainly exhibit the M1 phenotype, which contributes to inflammation and fibrosis in DKD. Studies have indicated that autophagy plays an important role in M1/M2 activation.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!